Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Nov 21, 2014 10:09pm

287 Views

Post# 23154408

RE:Pharma Discussions - Clarification

I wonder who the "new pharma" might be....

...and is that plural or singular? (Sounds to me that it might be plural, but I'm not sure.)

All quite interesting. Who knows where this might lead - or when. I don't.

Admittedly, this Winter seems like it's going to be a long one. But you never know when the sun might break out.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns